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INTRODUCTION: 
A vast variety of pharmaceutical research is directed at 
developing new dosage form. Orally disintegrating dosage 
form is the widely preferred commercial product among 
the various dosage forms. The oral cavity is the most 
favorable site for administration of orally disintegrating 
dosage form due to the ease of ingestion. Oral route is used 
for the administration of various dosage forms such as 
orally d isintegrating tablets , films, patches, wafers, 
chewing gums etc. In the recent trend orally disintegrating 
tablets gaining popularity because it is easy to admin ister 
and doesn’t requires additional water. Chewable tablets are 
palatable and can be chewed before swallowing. The orally  
disintegrating films can be administered in the oral cavity 
and disintegrates within a second to give better theuraptic 
action. Chewing gums are used for local and systemic 
treatment. Su itable drug candidates for such system 
include cardiovascular agents , neuroleptics, analgesic, 
antiallergics and drug for erectile dysfunction. Such a 
dosage form d isintegrates  quickly when placed on tongue; 
release the drug that dissolves in saliva. This results in 
greater bioavailability and rapid onset of action than 
conventional dosage form 
1
. 
ORALLY DIS INTEGRATING TABLETS : 
The centre for drug evaluation and Research defines orally 
disintegrating tablets as a dosage form –“A solid dosage 
form which disintegrates rapidly within a matter of 
seconds when placed under the tongue”. The disintegrating 
time for orally disintegrating tablet varies from seconds to 
minutes, depends upon the size of tablet and formulation.  
European pharmacopeia defined orally disintegrating 
tablets as-“Uncovered tablet which disperse before 
ingestion in the buccal cavity”. Different technological 
techniques such as freeze drying or moulding or direct 
compression etc.are used to prepare the formulat ion of this 
type in the pharmaceutical market
2 
DES IRED CHARACTERIS TICS OF ODT: 
1] Bioavailability  
2] Rapid drug therapy intervention is possible 
4. 
3] Sufficient mechanical strength 
4] A llow h igh drug loading 
9. 
5] Rapid onset of theuraptic action 
6] Good compatib ility with development technology 
7.
 
7] Leaves no residue in mouth after oral administration 
8] Stability  
9] Conventional packaging and processing equipments 
allows the manufacturing of tablets at low cost 
4, 9. 
10] Be compatib le with taste masking and other excipients  
ADVANTAGES  OF ODT: 
1] It can be administered to the patient who cannot 
swallow conventional dosage form such as bedridden 
patients, elderly and patient effected by renal failure and 
thus improves patient compliance 
6. 
2] It is suitable for bedridden, disabled, traveler and busy 
persons who does not contain water every time 
5. 
3] Good mouth feel property helps to mask the bitterness 
of medicines. 
4] Rapid drug therapy intervention. 
5] It provides rapid absorption of drugs and increased 
bioavailability. 
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6] It allows high drug loading. 
7] No chewing needed 
8. 
8] The risk of suffocation during oral admin istration of 
conventional formulat ion due to physical obstructions is 
avoided and provides safety. 
 
TABLE 1 : SOME OF THE DRUG CANDIDATES FOR ORALLY DISINTEGRATING TABLETS 
3, 10
. 
CATEGORY EXAMPLES   
Anti  Diabetics Glipizide,Tolbutamide,Glibenclamide,Tolazamide,Gliclazide, Chlorpropamide etc.  
Anti  Hypertensive  Minoxid il,Nimodip ine,Amlodipine,Terazosine HCl,  Prazosin HCl,Dilt iazem etc    
Anti  Histamines Loratadine,Cetrizine,Cinnarizine,Tripro lid ine,Fexofenadine etc  
Anti  Arrhythmics Quinid ine sulphate,Amiodarone HCl,Disopyramide    
Diuretics  Acetazolamide,Spironolactone,Furosemide,Amiloride,Ethacrynic acid etc  
Anti  Arrhythmics Quinid ine sulphate,Amiodarone HCl,Disopyramide  
Analgesics Ibuprofen, Ketoprofen, Diclofenac sodium, Mefenamic acid, Piroxicam, Oxyphenbutazone, 
Indomethacin etc. 
 
Antibacterial agents Penincillin, Rifampicin, Nalid ixicacid, Trimethoprim, Suphacetamide, 
  Ciprofloxacin,Tetracyclin,Doxycyclin etc.     
Anti  Depressants Notriptyiline HCl, Trazodone HCl,Amoxapine,Minaserin HCl etc  
Corticosteroids Hydrocortisone,Betamethasone,Beclomethasone,Prednisolone etc. 
Anti  Protozoal 
agents 
Metronidazole,Tinidazole,Benznidazole,Omidazole    
Anti  Helmintics Mebendazole,Albendazole,Livermectin,Dichlorophen, Thiabendazole,Praziquantal etc.   
Gastro-intestinal 
agents 
Ranit idine HCl, Famot idine,Cimitidine,Omeprazo le, Ondansteron HCl,Domperidone etc.   
 
DISADVANTAGES OF ODT’s: 
1] It requires proper packaging for safety and stabilization of stable drugs. 
2] It is hygroscopic in nature, so must kept in dry place 
4, 8. 
3] It shows the fragile, effervescence granules property
1. 
4] If not formulated properly, it  may leave unpleasant taste in mouth. 
5] Since the tablet having insufficient mechanical strength, so careful handling is required
3. 
TRADITIONAL TAS TE MAS KING TECHNOLOGIES IN ODTs  
17
: 
1] Taste masking by Ion-exchange Resins. 
2] Taste masking by coating with Hydrophilic Vehicles. 
3] Taste masking using Flavors and Sweeteners. 
4] Taste masking using Lipophillic Vehicles  
Table 2: Technologies Used For Masking the Taste of Active Ingredient
17, 18, 20
. 
S.No Technology Excipients Active 
Ingredient 
 Method 
1 Fluidized bed coating Methyl cellulose, HPMC, 
Acesulfame 
Tamoxifen, caffeine,  
acetaminophen 
Coating completed in3 
minutes. Internal temperature 
maintained at 115 degree F. 
MC and AS solution charged 
to fluidized bed drier.  
 
2 Pelletization process Dryblend-Aspartame, HPC and 
Gum arabic 
Loratidine Crushed ice was mixed with dry 
blend mixture to form Spherical 
particles. 
3 Infusion method Sucralose, Fluoxetine and PVP Fluoxetine Propylene glycol: water was used 
to mix dry blend HPMC was 
added. 
4 Agglomeration process Sweetner, HPMC, Silicon-di-oxide Polythiazide Sweetener solution sprayed on dry 
blend to form agglomerate 
Granules. 
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FORMULATION ASPECTS IN DEVELOPING ODT: 
ODT’s are formulated by several processes, which differ in  
their methodologies and vary in various properties such as: 
1] Taste and mouth feel
2. 
2] Mechanical strength of tablets 
6. 
3] Drug dissolution in saliva. 
4] Bioavaibility. 
5] Stability. 
6] Swalloability  
CHALLENGES IN FORMULATING ORALLY 
DISINTEGRATING TABLETS :  
1] Mechanical strength: 
In order to swallow ODTs to disintegrate in the oral cavity, 
they are either made of porous or soft molded matrices, 
which makes tablet friable and difficult to handle and 
hence requires peel-off blister packing which increases its 
cost
11, 12. 
2] Palatability: 
Since most drugs are unpalatable, orally disintegrating 
drug delivery system contains medicament in taste masked 
form 
13.
It dissolves in patient oral cavity, thus release the 
active ingredient which comes in contact with the taste 
buds
5
. 
3] Aqueous solubility: 
Water soluble drugs pose various formulat ion challenges 
results in freezing point depression and formation of glassy 
solids that may collapse upon drying. Such collapse can be 
prevented by using various matrix fo rming excipients like 
mannitol
11, 15. 
4] Amount of drug: 
The application for technologies used for ODTs is limited 
by the amount of drug into each unit dose
14
.The drug dose 
must be lower than 400mg for insoluble drugs and 60mg 
for soluble drugs
12. 
5] Size of tablet: 
The easiest size of tablet to swallow is 7-8mm while the 
easiest size to handle is 8mm.Therefore, tablet size that is 
easy to handle and easy to take is difficult to achieve.  
6] Hygroscopicity: 
Many orally disintegrating dosage forms are hygroscopic 
in nature
12,5
. Hence they need protection from humid ity. 
MECHANIS M OF ODTs
16
: 
It involves the following mechanis m –  
1] Incorporation of an appropriate disintegrating agent in 
the tablet formulation. 
2] For rapid d isintegration and dissolution of the tablet, 
water must quickly enter into tablet matrix.  
3] Tablet is broken down into smaller part icles. 
 
EXCIPIENTS US ED FOR PREPARATION OF ODTs 
5, 16,17,9
: 
1] Superdisintegrants-It increases the rate of 
disintegration and dissolution. For the success of orally  
disintegrating tablet, the tablet having quick dissolving 
property which is achieved by super 
disintegrants.Examples are- Crospovidone, MCC, Sodium 
starch glycolate, CMC, Carboxy methyl cellu lose and 
modified corn starch. 
2] Sweeteners and sugar based excipients-Sugar based 
excip ient act as bulking agents. They exhibit high aqueous 
solubility and sweetness and impart taste masking 
property. Examples are-Aspartame, Sugar derivative, 
Dextrose, Fructose, Mannitol, Sorbitol, Maltose etc. 
3] Flavors-It increases patient compliance and 
acceptability. Examples are-Vanilla, Citrus oil, Fruit  
essence, Eucalyptus oil, Clove oil, Peppermint oil etc. 
4] Surface Active agents-It reduces interfacial tension and 
thus enhances solubilizat ion of ODTs.Examples are-
Sodiumlaurlysulfate, Sodiumdoecylsulfate, 
Polyoxyethylene sorbitan fatty acid esters , 
Polyoxyethylene steartes etc. 
5] Binder-It maintains integrity of dosage form. Examples 
are-PVP, Polyvinylalchol, Hydroxy propyl 
methylcellu lose. 
6] Colour-It enhances appearance and organoleptic 
properties of dosage form. Examples are-Sunset yellow, 
Red iron oxide, Amaranth
3
. 
7] Lubricants-It helps reduces friction and wear by 
introducing a lubricating film. Examples are-Stearic acid, 
Magnesium stearte, Zinc stearte, Talc, Polyethylene 
glycol, Liquid paraffin, Colloidal silicon-di-oxide etc. 
8] Fillers-It enhances bulk of dosage form. Examples are-
Mannitol, Sorbitol, Xylitol, Calcium carbonate, 
Magnesium carbonate, Calcium sulfate, Magnesium 
trisilicate etc. 
TECHNIQUES US ED FOR PREPARATION OF 
ODT’s: 
A] Conventional techniques : Various conventional 
techniques are available for preparat ion of ODT’s are- 
1] Freeze drying: It is a process in which water is 
sublimated from the product after freezing. In this heat 
sensitive drugs and biological are dried at low temperature 
that allows removal of water by sublimation
25
. 
2] Sublimation: In these, inert solid ingredient that 
volatilized readily was added to other tablet ingredient and 
mixture is compressed into tablets. The volatile material 
was then removed by the process of sublimation
19, 37
. 
3] Spray-drying : It  produces very fine and highly porous 
powder. Tablets prepared from spray drying disintegrate 
within 20 sec when immersed in an aqueous medium
27
. 
4] Molding : In these, water soluble ingredients are used to 
prepare molded tablets so that tablet dissolves rapidly. 
Molded tablets are very less compact then compressed 
tablets and exh ibit porous structure for rapid d issolution. 
5] Mass-extrusion: It involves softening the active blends 
using the solvent mixture of water soluble PEG. The 
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granules of bitter tasting drugs are coat by dried cylinders 
and hence masking their b itter taste
26, 28
. 
6] Disintegrates addition: Because of its easy 
implementation and cost effectiveness, it is a popular 
technique for formulating ODT’s.The basic principle 
involved is addition of superdisintegrants in optimum 
conc. 
7] Direct compression: It is the easiest way of 
manufacturing tablets. It consists of a limit ing number of 
processing steps, conventional equipments and commonly  
available excipients. Also it requires few unit operations as 
compared to wet granulat ion
7, 20
. 
B] Patented technologies: Various patented technologies 
available for preparat ion of ODT’s are- 
1] Flashtab Technology: In these, tablets consists active 
ingredient in the form of micro crystals. It is conventional 
tableting technology.Prographarm laboratories have 
patented the flashtab technology
29
. 
2] Wow tab Technology: It involves adequate dissolution 
rate and hardness .It is patented by “Yamanouchi 
Pharmaceuticals Co”. Wow means without water. 
3] Flash dose Technology: It requires greater surface area 
for dissolution. Flash dose tablets consist of self binding 
shear form matrix termed as “floss”. It has been patented 
by “Fuisz”. 
4] Durasolv Technology: It is a patented technology of 
“CIMA” labs. It consists of druf, fillers and lubricant. It  
requires low amount of active ingredient
23
. 
5] Zydis Technology:  It involves quick dissolution, 
increased bioavailability and self-preserving. It involves 
softening the active blends using the mixture of methanol 
and polyethylene glycol.  
6] Orasolv Technology: It is patented technology of 
“CIMA” labs. It involves quick dissolution and taste 
masking of active ingredient
29, 37
. 
EVALUATION OF ODT’s9, 11, 18: 
Various evaluating parameters of ODT’s are- 
1] Weight variation. 
2] Hardness. 
3] Friability Test. 
4] Disintegration Test. 
5] Mechanical strength. 
6] Uniformity of d ispersion. 
7] Wetting time. 
8] In-Vitro d isintegration time. 
9] In-Vitro d issolution time. 
10] Stability studies. 
Table 3: Some of the Marketed Products of ODT’s17, 22, 30, 35: 
S.NO. BRAND NAME DRUG/ PHARMACEUTRICAL  COMPANY 
1 Benadryl fast melt  Diphenhydramine  Pfizer  
2 Rofaday MT Roficoxib   Lupin   
3 Domray MD Domperidone  Ray Remedies 
4 Benadryl fast melt  Diphenhydramine  Warner Lambert  
5 Torrox MT Roficoxib   Torrent  
6 Feldene melt Piroxicam   Pfizer  
7 Febrectol  Paracetamol  Prographarm 
8 Kemstro  Baclofen   Schwarz Pharma 
9 Mosid MT  Mosapride  Torrent  
10 Maxalt-MLT Rizatriptan Benzoate  Merck  
11 Nimulid MD Nimusulide  Panacea  
12 Nulev   Hyoscyamine sulfate  Schwarz Pharma 
13 Pepcid ODT Famotidine   Merck  
14 Klonopin Wafers Clonaxepam  Roche  
15 Cibalginadue FAST Ibuprofen   Novartis Consumer Health 
16 Olanex instab Olanzepine   Ranbaxy  
17 Zofran ODT Ondansetron  GSK  
18 Zyprexa  Olanzepine   Eli lily   
19 Romilast  Montelukast  Ranbaxy lab  
20 Olanex instab Olanzapine   Ranbaxy lab  
 
BUCCAL PATCHES: 
Buccal route of drug delivery provides direct access to the 
systemic circulation through the jugular vein by passing 
the first pass hepatic metabolism and hence increases its 
bioavailability
24
.The buccal patches can solve the problem 
of short residence time of oral gel on mucosa. However 
buccal patches can offer greater advantages and comfort  
then other devices such as low enzymat ic activ ity, greater 
accessibility, easy withdrawal, painless admin istration, and 
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facility to induce permeation enhancer or ph modifier in  
the formulat ion, versatility in designing as unidirectional 
or mult idirect ional release system for local or systematic 
action
19
. 
ADVANTAGES  OF BUCCAL PATCHES : 
1] It is well known for their good accessibility to the 
membrane that lines the oral cavity, which makes 
application comfort 
24
. 
2] The drug gains direct entry into the systemic circulat ion 
in buccal admin istration, thereby passing the first pass 
effect. In these, rate of drug absorption is not affected by 
gastric emptying rate 
22
. 
3] In these, drugs are absorbed from the oral cavity and 
transported through the deep facial vein, internal jugular 
vein, braciocephalic vein into the systemic circulation.  
4] The buccal drug delivery system easily administered 
into the buccal cavity and hence exh ibit better patient 
compliance
19
. 
COMPOS ITION OF BUCCAL PATCHES 
21, 30
: 
1] Active ingredient: It contains API. 
2] Diluents: Lactose DC is selected as a diluents its 
flavoring characteristics, high aqueous solubility and its 
physic-mechanical propert ies. Other examples are starch 
and microcrystalline starch. 
3] Polymers: Hyroxyethyl cellulose, 
Hydroxypropylcellulose, Polyvinylpyrro lidone, 
Polyvinylalchol, Carbopol etc. 
4] Backing layer: Ethyl cellulose etc. 
5] Sweetening agents: Aspartame, mannitol, sucralose etc. 
6] Flavoring agents: Menthol, vanillin, clove oil etc. 
7] Plasticizers : PEG-400, 100, Propylene glycol etc. 
8] Penetration enhancer : Cyanoacrylates etc. 
FACTORS AFFECTING BUCCAL ABSORPTION : 
There are two factors which affect buccal absorption- 
1] Membrane factors: It involves surface area for 
absorption, mucus layer of salivary pellicle, intercellu lar 
lip ids of epithelium and degree of keratinizat ion 
36
. 
2] Environmental factors : These include saliva and 
salivary glands. The thin film of saliva coats throughout 
the buccal mucosa and called the salivary films. The 
thickness of salivary film is 0.07 to 0.10mm. The minor 
salivary glands are located in the epithelial reg ion of 
buccal mucosa and constantly secrets mucus on surface of 
buccal mucosa 
24
. 
METHOD OF PREPARATION OF BUCCAL 
PATCHES 
35
: 
There are two methods available fo r preparation of buccal 
patches- 
1] Direct milling: 
In this method, drugs and excipients are mixed by direct  
milling without the need of water. Then the resultant 
material is rolled on a release liner. The backing material is 
then laminated. In these method patches are made without 
solvent. 
2] Solvent casting: 
In these, all patch excipient and drug are co-dispersed in an 
organic solvent and then coated on to a sheet of release 
liner. After solvent evaporation a backing material is 
laminated onto the sheets of coated release liner until the 
desired thickness is achieved. 
EVALUATION OF BUCCAL PATCHES  
22, 30, 35
: 
1] Thickness measurements: 
The thickness of each film is measured by using electronic 
digital micrometer at five d ifferent locations. 
2] Thermal analysis study: 
It is done by using Differential scanning calorimetry. 
3] Surface PH: 
It is measured by means of a ph paper placed on the 
surface of a swollen patch. Buccal patches are swell when 
placed on the surface of agar plate.  
4] Morphological characterization: 
It is done by using scanning electron microscope. 
5] Swelling study: 
As we know buccal patches are swell when placed on the 
surface of agar plate. After 1 hour plates are removed from 
the gel plates and excess water is removed using filter 
paper. 
6] Water absorption capacity test: 
Circular patches are prepared in simulated saliva are 
allowed to swell on agar plate and kept in an incubator. At 
various time interval samples are weighed and left to dry 
in a dessicator over anhydrous calcium chloride at room 
temperature and final constant weight is recorded. 
7] In vitro drug release: 
To study the drug release from mult ilayered and bilayered  
patches (USP) XXX111-B rotating paddle method is used. 
Phosphate buffer ph 6.8 is used as a dissolution media. The  
in vitro buccal permeation through the buccal mucosa is 
performed using Franz type glass diffusion cell.  
8] Permeation study of buccal patch: 
Phosphate buffer ph 6.8 is filled in receptor compartment 
and hydrodynamics is maintained by stirring with a 
magnetic bead. Samples are withdrawn at predetermined 
time intervals and analyzed. 
9] Measurement of mechanical properties:  
It includes tensile strength and elongation at break is 
evaluated using a tensile tester. Clamps are designed to 
secure the patch without crushing it during the test, the 
lower clamp held stationary and strips are pulled apart by 
the upper clamp. When the tip breaks the force and 
elongation of film is noted. 
10] Stability study in human saliva: 
The human saliva is collected from humans and stability 
study of bilayered and mult ilayered patches is performed  
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in human saliva. Buccal patches are placed in separated 
petridish containing 5ml of human saliva and placed in an 
oven. At regular time interval, dose formulat ion with better 
bioavailability is  needed 
19
. 
ORALLY DIS INTEGRATING FILMS: 
Orally disintegrating films is new drug delivery system for 
the oral delivery of drugs. Because of convenience and 
ease of use over other dosage form, orally disintegrating 
films have been introduced in the market 
32
.Orally  
disintegrating films disintegrate within few seconds when 
placed on the tongue without the need of water. It was 
developed on the basis of transdermal patch technology. 
Recently oral films containing breath fresheners, API and 
vitamin supplements 31. 
FEATURES OF ORALLY DIS INTEGRATING 
FILMS  
32
: 
1] Available in various shape and size.  
2] Excellent mucoadhesion. 
3] Rapid release. 
4] Unobstructive. 
5] Thin elegant film. 
6] Fast disintegration. 
ADVANTAGES OF ORALLY DIS INTEGRATING 
FILMS : 
1] They can be administered anytime without water.  
2] They are portable and flexible in nature 
31
. 
3] They have accurate dosing in safe and effecious format.  
4] Taste masking of drug should be done. 
5] They provide rapid dissolution and disintegration in the 
oral cavity due to its large surface area 
33
. 
6] They are suitable for geriatric and pediatric patients. 
7] It has potential to improve the onset of action and 
increase the safety of medicament.  
8] It provides new business opportunities like patent 
extension, product promotion and product differentiat ion 
34
. 
DISADVANTAGES OF ORALLY 
DISINTEGRATING FILMS  
38
: 
1] High dose is avoided in orally disintegrating films  
formulat ion. 
2] Special packing is required since they are temperature 
and moisture sensitive. 
3] There is a problem of dose uniformity in fo rmulat ing 
ODF’s. 
FORMULATIONS CONS IDERATION IN ODF’s 32, 33: 
1] Active pharmaceutical ingredient (API).  
2] Film forming polymers. 
3] Saliva simulating agent. 
4] Sweetening agent. 
5] Colouring agent. 
6] Plasticizers. 
7] Flavoring agents’ 
METHODS OF PREPARATION OF ODF’s:  
There are various methods for preparation of ODF’s which 
are enlisted below- 
1] Solvent casting method 
39
: 
In this method all water soluble excipients  are dissolved in 
water and after then water soluble polymers and drug are 
added to form a homogeneous mixture at high shear 
processor. Finally solution is poured into the Petri plate for 
drying. In this method, solvent evaporates at high 
temperature. 
2] Semisolid casting method: 
In these method water soluble polymers and acid insoluble 
polymers are added which is prepared by the sodium 
hydroxide and ammonium hydroxide. At last, sufficient 
amount of plasticizer is also added to form a gel. Cellulose 
acetate phthalate and cellulose acetate butyrate are acid 
insoluble polymers which are used to prepare films. The  
film thickness is 0.015 to0.05 inches 
40
. 
3] Solid dispersion extrusion: 
In this method solid dispersion is prepared and immiscible 
components are extruded and finally mixed with the drug. 
Finally with the help of dies solid dispersion are shaped in 
to films 
34
. 
4] Rolling method: 
In this method, a drug and polymer suspension is prepared 
containing water or alcohol as solvent and subjected to the 
roller 
41
.The suspension is then add on drum for 
evaporating the solvent and cutted into desired size and 
shapes 
33
. 
5] Hot melt extrusion: 
In these method, drug is mixed with carrier in the solid 
form and and dried granular material is put into the 
extruder
42
.The screw speed should be 15rpm.In the 
extruder solid for carrier and drug is melt and placed in to 
dies and cutted into desired size and shapes
41
. 
6] Freeze dried wafer: 
In this method, dehydration of water occurs 
41
. It reduces 
pressure from surrounding and allows the water in material 
to sublime directly .It is also called as lyophilisation 
method. 
DIFFERENT TECHNOLOGY US ED IN ODF’s: 
Technology used in formulating ODF’s are enlisted below- 
1] Solu leaves. 
2] Wafertab. 
3] Micap. 
4] Foam burst. 
5] Xgel. 
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EVALUATING PARAMETERS OF ODF’s:  
Various evaluating parameters of ODF’s are- 
1] Thickness  
42
: 
It can be measured by micrometer screw guage or vern ier 
calipers. For content uniformity and uniform film 
thickness, it can be checked at five different points  by 
calibrated dig ital micrometer. 
2] Mechanical properties : 
a) Tensile strength- It is point at which film is break 
32 
Tensile strength = Load at failure× 100÷ Film thickness× 
Film width 
b) Percent elongation: It is calculated by the following 
formulae 
% elongation= Increase in length×100/Orig inal length 
3] Folding endurance: 
Folding endurance value is determined by the number of 
times the film is folded without breaking. 
4] Tear resistance: 
Tear resistance value is the maximum force or stress 
required to tear the specimen [43, 45]. It is expressed in 
Newton’s  or Pound-Force. 
5] Surface ph of film: 
It can be measured by placing the film on the surface 
of1.5%w/v agar gel by placing ph paper on film.  
6] In vitro disintegration time: 
In this method, films are placed in the mouth of volunteer 
and check the time to disintegrate the film 
44
. 
7] Contact angle: 
It is measured by goniometer.In these method distilled  
water drop placed on dry film and picture is taken within 
10 sec for angle determination 
32
. 
8] In vitro dissolution test: 
It is performed in USPX111 type 11 apparatus in 0.1N 
HCL and 6.8 phosphate buffer. The samples withdrawn at  
various time intervals and analyzed spectrophotometrically  
42
. 
9] Drug content and drug uniformity: 
It is determined by estimating the API content in 
individual film 
46
. It is also determined by specification in  
different pharmacopeia. 
10] Trans parency: 
It is determined using a simple UV spectrophotometer 
46
.In 
these film samples are cut into rectangles and kept on 
internal side of spectrophotometer cell. 
11] Taste evaluation: 
It is going with panel of volunteers and the test sensors 
analyzed the sweetness level of taste masking agents. 
12] Packaging: 
The most commonly used packaging format is aluminum 
pouch. Rapid card is used for packaging of Rapid films  
which is patented and proprietary packaging system of 
APR-Labtech 
41, 44
. 
Table 4:  Commercially Thin Film Oral Dosage Form Products
32, 41
: 
S.No. Product Manufacturer Active  Pharmaceuticalagent 
1 Triaminic Novartis  Dextromethorphan HBr  
2 Triaminic Novartis  Diphenhydramine HCl 
3 Theraflu Novartis  Dextromethorphan HBr 
4 Gas-X Novartis  Simethicone  
5 Sudafed Pfizer  Phenylephrine HCl  
6 Benadryl Pfizer  Diphenhydramine HCl 
7 Chloraseptic Prestige  Benzocaine Menthol  
8 Suppress InnoZen  Menthol   
9 Orajel Del  Menthol/Pectin  
10 Listerine Pfizer  Cool mint   
 
CHEWING GUMS AND CHEWABLE TABLETS 
31, 
55
: 
Chewable tablets can be taken without water and chewed 
before swallowing. They are suitable for children’s  
≥4years.They contains coated particles of active drugs. 
The chewable tablets have palatable taste and contain non-
critical excipents. 
For children’s  above 2 years chewable tablets contain 
cyclodextrin for taste masking and solubilization. It seems 
to be safe for oral use. Use of ion resins or cyclodextrins is 
used for taste masking of adults dosage form. It is not 
always acceptable for childrens.It increases bioavailability 
by immediate d isintegration, patient acceptance and patient 
convinence.A common problem of chewable tablet is that 
the membranes coated the active particles can break. The 
drug unpleasant taste is often perceived by the patient due 
to the breakdown of membranes 
54
. 
Chewing gum tablet consist of two cohered chewing gum 
modules. It was formed by compression of chewing gum 
granules. The compressed chewing gum tablet composed 
of chewing gum ingredients with acceptable rheological 
properties. Addition of water or heat is not required for 
formulat ing chewing gums. A palatable, edib le soft 
chewable medicat ion vehicle was patented by Paulson et 
al.Chewing gums takes 10-20 minutes for complete release 
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of drug. This are used for systemic or local 
treatment.Superpep® travel gum is a p roduct for children’s  
≥6 years. It contains four sweeteners such as aspartame, 
sucrose, sorbitol and sodium saccharine to mask the taste 
for entire chewing t ime. 
ADVANTAGES  OF CHEWING GUMS  
47, 48
: 
1] It does not required water to swallow. 
2] It is suitable for children’s and patients having difficu lty 
in swallowing. 
3] It enhances bioavailability of drug and avoids first pass 
metabolism. 
3] It simulates flow of saliva in mouth. 
5] It causes fast onset of action due to rapidly release of 
active ingredients. 
6] It neutralized plaque acids. 
DISADVANTAGES OF CHEWING GUMS: 
1] It contains sorbitol which causes diarrhea and flatulence 
51
. 
2] Cinnamon, flavoring agents like additives present in 
chewing gum may causes ulcers in oral cavity.  
3] Pro longed chewing of chewing gum results in pain in  
facial muscles 
49
. 
COMPOS ITION OF CHEWING GUMS  
50
: 
1] Water insoluble gums- 
These contain Elastomers, Resins, Fats and Oil and 
Inorganic fillers. 
2] Water soluble gums- 
These contain high intensity sweeteners, Bulk sweeteners, 
Flavouring agents, Softners, Emulsifiers, Colours and 
antioxidants. 
Table 5: List of S ome of the Commercialy Available Chewing Gums  
53
: 
S. N. TRADE 
MARK™  
 ACTIVE 
SUBSTANCES 
 AIM  COMMERCIAL 
AVAILIBILITY 
1 Aspergum  Aspirin  Pain Relief  North America 
2 Nicorette  Nicotine  Smoking cessation World wide 
3 Nicotinelle Nicotine  Smoking cessation Western Europe, Australia 
4 Travell  Dimenhydrinate Travel illness Italy, Switzerland 
5 Superpep  Dimenhydrinate Travel illness Germany, Switzerland 
6 Endekay Vit C Vit C  General health United Kingdom 
7 Stamil Vit C Vit C  General health Australia  
8 Brain  DHA and CCE Enhanced brain activity Japan  
9 Stay alert  Caffeine  Alertness  USA  
10 Café Coffee Caffeine  Alertness  Japan  
11 Buzz Gum  Guarana  Alertness  United Kingdom 
12 Go Gum  Guarana  Alertness  Australia  
13 Chroma slim CR  Diet  USA  
14 Chooz  Calciumcarbonate Stomach acid , neutralization USA  
 
DIFFERENT METHODS OF PREPARATION OF 
CHEWING GUMS: 
1] Fusion/Traditional Method 
52
: 
In this method, components  of gums, sweeteners, 
softeners, active ingredients and excipient are added in a 
kettle mixer. This is then passing through a series of 
rollers. In these processes, a light coating of finely  
powdered sugar is added to the gum. At last, gum is cutted 
into desired shape and size. 
2] Cooling, Grinding and Tabletting Method 
48
: 
This method is mainly used to lower the moisture content 
and reduces the problems mentioned in conventional 
method. 
To achieve desired properties of chewing gum and to 
facilitate cooling, grinding certain additives are added to 
the chewing gum composition such as - 
a) Use of grinding agent. 
b) Use of Anticaking agent. 
For Tabletting a Fluidized Bed Reactor can be used. In 
these method after the removal of coolant from the 
powder, it can be mixed with other ingredients such as 
binders, lubricants, sweeteners, colouring agent etc.in a 
suitable blender such as high shear mixture 
48
. 
3] Use of Direct Compression Chewing Gum Excipients  
51
: 
This method can be used to overcome the limitations of 
melting and freezing method. In these methods, chewing 
gum can be manufactured under CGMP conditions and 
complies with Food Chemical Codex and FDA 
specifications. So they can be considered as (GRAS) 
“Generally Regarded as Safe” 47. 
APPLICATIONS OF CHEWING GUMS: 
1] It is used to inhibit plaque growth.  
2] It is used to mask the bitter taste of chlorhexidine 
49
. 
3] It is used to cure and prevent oral disease. 
4] It is used to provide a prolonged local effect 
52
. 
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5] It contains active substances like guaran, chromium, 
caffeine to treat obesity. 
6] It is used in treatment of headache, minor pains and 
muscular aches. 
7] It is also beneficial for Allergy, Cold and Cough, 
Xerostomia, Acid ity, Anxiety, Motion sickness etc 
47
. 
ORAL WAFERS 
55
: 
Oral wafers are also called or dispersible strips. These are 
thin films of 2-8cm square area and20-500µm thickness. It 
contains ≤50 mg of API.Wafers are administered on the 
tongue and dissolves in the mouth without intake of water 
within a few seconds. Now  a days, few OTC products are 
available for preschool childrens.The products contains 
many excipients such as film forming agents derived from 
starch and cellulose,flavours,colouring agents, sweeteners 
and traces of class 3 residual solvents. The residual 
solvents act processing aids. 
Oral wafers are usually provided as unit dose in child 
proof pouches. Recently, the first prescription-only oral 
wafer is Setofilm® approved in Europe for use in 
children’s  from 6 months onward by Applied Pharma 
Research and Labtec and MonoSol Rx.  
SPECIAL FORMULATIONS- LOLLIPOPS AND 
GUMMY BEARS: 
Special oral fo rmulat ions are lollipops and Gummy bears. 
Lo llipops are for children’s  above 3 years and gummy 
bears are for ch ild ren’s  above 3 years. These are sweet in  
taste. Due to its sweet taste they ate attractive to children’s  
and parents can easily administered drug to their 
children’s . 
Lo llipops are formulate depend upon the individual taste. 
It is trendy in US compounding pharmacies 
55
.However it  
should be labeled that these “special” formulation are not 
“sweet” and kept out from reach of children’s . 
CONCLUS ION: 
The area of formulating orally disintegrating dosage forms 
is aims at increasing the patient compliance and decreasing 
the disintegration time. It also aims of masking the 
objectionable taste of active ingredients. As compared to 
other complicated processes such as freeze drying etc., 
formulat ion of orally disintegrating dosage form is easy 
and overall cost of manufacturing is low. The potential of 
orally disintegrating dosage form to disintegrate in the oral 
cavity within seconds, fast onset of action, increasing 
patient compliance and taste masking of active ingredient 
makes it an attractive drug delivery form. However ,an  
addition of active ingredient in dosage form like orally  
disintegrating tablets, orally disintegrating films, oral 
wafers, buccal patches and chewing gums are excepted to 
provide a highly acceptable means of delivering drug to  
geriatric and pediatric patients.So.in forth coming years 
oral drug delivery becomes a much popular drug delivery.  
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